2007—2010年北京积水潭医院门诊抗骨质疏松药应用分析

Utilization of Anti-osteoporosis Drugs in Outpatients of Beijing Jishuitan Hospital During 2007-2010 Period

目的:了解我院抗骨质疏松药的应用现状及趋势。方法:根据抗骨质疏松药的结构及作用机制不同进行分类,采用WHO推荐的限定日剂量(DDD)频度分析法,对我院2007—2010年抗骨质疏松药的销售金额、用药频度(DDDs)及限定日费用(DDC)等进行回顾性分析。结果:我院抗骨质疏松药的销售金额呈逐年上升趋势,降钙素类抗骨质疏松药销售金额占总销售金额的40%,碳酸钙D3片(钙尔奇D 600片)及骨化三醇胶丸(盖三淳胶丸)DDDs排序前2位,鲑鱼降钙素注射液(密盖息注射液)DDC排序居第1位。结论:我院抗骨质疏松药使用基本合理,随着我国人口的老龄化和民众保健意识增强,抗骨质疏松药市场潜力巨大。

OBJECTIVE： To investigate the status quo and tendency of the use of anti-osteoporotics in our hospital.METHODS： The anti-osteoporosis drugs were classified based on their structures and action mechanism.The use of anti-osteoporosis drugs in our hospital during 2007-2010 period was analyzed retrospectively regarding consumption sum,DDDs and daily drug cost（DDC） by using DDD（Defined daily dose） analysis recommended by WHO.RESULTS： The consumption sum of anti-osteoporosis drugs in our hospital during 2007-2010 period witnessed a year-on-year increase,with calcitonin anti-osteoporosis accounting for 40% of total.Caltrate D3 and Calcitriol Soft Capsules dominated the first two places on the list of DDDs,and Salmon Calcitonin Injection was ranked at the first in DDC.CONCLUSION： The use of anti-osteoporosis drugs in our hospital was reasonable on the whole.With the aging of the population and the strengthening of public awareness on health,the anti-osteoporosis drugs enjoy a potential market.